Danaher subsidiary Integrated DNA Technologies launched two in vitro diagnostic (IVD) NGS library‑preparation assays—Archer FusionPlex‑HT Dx and Archer VariantPlex‑HT Dx—marking a strategic move from research‑use to clinical diagnostics. IDT acquired the Archer portfolio from Invitae in 2022 and adapted its anchored multiplex PCR chemistry for formalin‑fixed paraffin‑embedded and fresh tissue oncology testing. The IVD launch aims to help clinical labs navigate shifting regulations, including Europe’s IVDR, and positions IDT against established competitors in clinical NGS testing.